Isu Abxis Co Ltd
KOSDAQ:086890
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Isu Abxis Co Ltd
Total Equity
Isu Abxis Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Isu Abxis Co Ltd
KOSDAQ:086890
|
Total Equity
₩114.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
|
Celltrion Inc
KRX:068270
|
Total Equity
₩17.2T
|
CAGR 3-Years
61%
|
CAGR 5-Years
39%
|
CAGR 10-Years
27%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Equity
₩149.4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Equity
₩66.4B
|
CAGR 3-Years
113%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Equity
₩445.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
28%
|
CAGR 10-Years
28%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Equity
₩154.7B
|
CAGR 3-Years
31%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Isu Abxis Co Ltd
Glance View
ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
See Also
What is Isu Abxis Co Ltd's Total Equity?
Total Equity
114.5B
KRW
Based on the financial report for Dec 31, 2025, Isu Abxis Co Ltd's Total Equity amounts to 114.5B KRW.
What is Isu Abxis Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
9%
Over the last year, the Total Equity growth was 13%. The average annual Total Equity growth rates for Isu Abxis Co Ltd have been 21% over the past three years , 21% over the past five years , and 9% over the past ten years .
